Objectives: CD4 þ T-cell depletion from HIV infection leads to a global decline in antihepatitis C virus (HCV) envelope neutralizing antibody (nAb) response, which may play a role in accelerating liver fibrosis. An increase in anti-HCV nAb titers has been reported during antiretroviral therapy (ART) but its impact on HCV remains poorly understood. The objective of this study is to determine the effects of ART on long-term HCV evolution.
Introduction
Over 35 million people globally are living with HIV [1] , and a quarter of these individuals are coinfected with hepatitis C virus (HCV) [2] . Compared with HCV monoinfection, HIV coinfection accelerates HCVrelated liver fibrosis, cirrhosis, and hepatocellular carcinoma, increasing the overall mortality [3, 4] . With effective antiretroviral therapy (ART), liver disease has surpassed AIDS to become a leading cause of hospitalization and death in this coinfected population [5] .
The mechanisms underlying accelerated liver disease in HIV-HCV coinfection remain poorly understood. During the transition from acute to chronic HCV infection, humoral immune response initiates late but then broadens and persists, whereas cellular immune response wanes over time [6] [7] [8] [9] [10] . In chronic infection, cellular immunity is largely dysfunctional because of HCV-induced mechanisms involving PD-1, RIG-1 and others [11] [12] [13] [14] . Without reversal of T-cell exhaustion, humoral immunity alone, specifically neutralizing antibodies (nAbs), remains ineffective in clearing chronic HCV infection [15] . However, nAbs can block HCV propagation in vitro and in vivo, potentially modulating disease progression in chronic HCV [7, [16] [17] [18] [19] [20] [21] . HIV infection causes CD4 þ T-cell depletion and progressive T-cell dysfunction, which may influence nAbs functions [22, 23] . Bailey et al. [24] recently reported a significant reduction of anti-HCV envelope binding antibody titers, neutralizing antibody (nAb) titers, and nAb breadth in patients who had low CD4 þ T-cell counts after incident HIV infection. Lee et al. [25] demonstrated that HIV/HCV coinfected patients who received ART developed increased anti-HCV nAb titers. These findings indicate that HIV coinfection decreases HCV-specific nAb response, raising the possibility that preserving or restoring anti-HCV humoral immunity with ART may play a role in decreasing the rate of liver fibrosis progression.
Studies of viral dynamics and evolution can provide important insights into host-virus interactions. To date, few studies have investigated the effects of HIV coinfection and ART on HCV quasispecies evolution. An early study showed some positive selections against the hypervariable region (HVR)-1 of HCV envelope in patients receiving ART [26] . Another study showed a decreased HVR1 complexity and diversity in HIV/HCV coinfected patients who progressed to end-stage liver disease compared with those with compensated chronic hepatitis [27] . HCV genome is under constant selective pressure from host immunity. Envelope (E1E2) gene sequences are selected primarily by nAbs, whereas nonstructural genes (p7, NS2-NS5B) are selected by cellular immunity [7, 8, 20, [28] [29] [30] . Thus, a comparison of HCVevolutionary rates between structural (i.e. envelope) and nonstructural (e.g. NS3) gene sequences may provide information about the relative importance of humoral and cellular immunity.
One major obstacle in defining viral quasispecies is quantifying the relative proportions of different sequence variants in the overall viral population. Both clonal sequencing and end-point limiting-dilution PCR are labor intensive, and their sequencing depth is limited by the numbers of clones that could be analyzed. Highthroughput next-generation sequencing (NGS) technologies yield hundreds of thousands of sequence reads, but technical artifacts during sample preparation, including PCR and sequencing errors, template resampling, and PCR amplification bias, are known to skew the proportion and accuracy of viral variants in a quasispecies population. To overcome these artifacts, Jabara et al. [31, 32] developed a Primer-ID approach, which incorporates a random sequence tag during reverse transcription to the cDNA copy of each RNA template. Because each initial template is tagged with a unique Primer-ID barcode sequence, technical artifacts from allelic skewing, template resampling and nucleotide misincorporation are corrected by generating a consensus sequence for each unique Primer-ID. However, deep sequencing using the Roche/454 pyrosequencing platform introduces a large number of homopolymeric errors that complicates automated sequence alignments and bioinformatics analysis [33] [34] [35] [36] . Furthermore, because the Primer-ID strategy requires a large number of reads for consensus calls, the lower sequencing throughput of Roche/454 limits the number of samples that could be analyzed simultaneously. Thus, overcoming these technical challenges could allow for more accurate and rapid determination of authentic quasispecies population structure.
Here, we examined the evolution of HCV E1E2 envelope (structural) and NS3 (nonstructural) gene segments in HIV/HCV coinfected patients receiving either early or delayed ART. We found significantly higher rates of sequence evolution for HCV envelope in patients who had early ART and CD4 þ T-cell recovery compared with those with progressive CD4 þ T-cell depletion due to delayed ART. This difference in evolutionary rates between the two groups was not observed for NS3. Using a single-variant sequencing (SVS) approach that modifies the primer-ID strategy for sequencing on the Illumina platform, we not only constructed authentic HCV quasispecies but also identified naturally occurring resistance-associated variants circulating at less than 0.1% of the viral population. To our knowledge, this is the first study that demonstrates the effects of CD4 þ T-cell recovery from suppressive ART on long-term evolution of HCV quasispecies.
Materials and methods
Samples and methods Serum samples from patients with HIV/HCV coinfection were identified and selected from the University of Pennsylvania Center for AIDS Research (CFAR) repository. HCV RNA was extracted from serum samples using QIAmp Viral RNA kit (Qiagen, Valencia, California, USA). CDNA was synthesized using Super-Script III Reverse Transcriptase (Invitrogen, Carlsbad, California, USA) and RT primers that added random sequence tags to cDNA copies of viral RNA templates ( Figure S1 http://links.lww.com/QAD/A854). E1E2 and NS3 gene segments were amplified by nested-PCR followed by gel extraction. Pooled DNA library was sequenced on an Illumina MiSeq sequencer. Following a Q30 filter that removed low-quality reads, a total of 25.7 Gigabases of nucleotides were generated. For each unique sequence tag, a consensus sequence was determined using MAFFT (kazutaka.katoh@aist.go.jp, Japan; http://mafft.cbrc.jp/alignment/software/), based on an alignment of at least three reads that share the same sequence tag. Nucleotide sequences have been deposited in NCBI SRA under BioProject accession number PRJNA290532. Additional details on molecular biology and bioinformatics methods can be found in section Materials and Methods.
Statistical analysis
Mann-Whitney rank sum test was used to calculate significance of nonsynonymous substitution rates between early versus delayed ART groups or between different gene segments; Student's t test was used when normality was satisfied. A paired t test was used to compare the number of drug resistant mutations called by consensus and raw sequences from the same samples. A P value of <0.05 was considered statistical significant.
Results

Patients and samples
We queried the specimen repository at University of Pennsylvania Center for AIDS Research (CFAR) and selected six patients that had detailed clinical and laboratory data and a sufficient number of samples available, and also met the following criteria: HIV and HCV antibody positivity, followed for at least 5 years, received either early ART with CD4 þ T-cell recovery of more than 200 cells/ml between the first and the last samples (referred to as the 'early ART' group below), or delayed ART with a decline of CD4 þ T-cell counts of more than 200 cells/ml between the first and the last samples (the 'delayed ART' group). A total of six patients were included with three patients in each group (Fig. 1 ). The average duration of follow-up was 10.8 years.
Single-variant sequencing identified authentic hepatitis C virus quasispecies at both individual and population levels
Over 16 million paired-end Illumina reads (over 9 billion bases) were filtered using a set of stringent criteria to remove low-quality reads (Fig. 2) . A total of 91 326 (51 099 for E2 and 40 227 for NS3) consensus sequences were generated, averaging 1054 (range 233-5032) consensus sequences per sample from an average of 147 387 (range 26 169-328 582) raw reads. Approximately 75% of consensus sequences were formed using 3-100 reads, whereas the remaining 25% were built from over 100 reads (maximum 98 124 reads per consensus sequence).
To calculate the background error rate, we synthesized HCV RNA in vitro using a plasmid containing subtype 1a HCV sequence (H77c) [37] . We amplified the E1E2 gene segments containing the hypervariable region 1 (HVR1), and an NS3 gene segment of the in vitro transcript using the SVS method. We then compared HCV quasispecies before and after SVS correction ( Figure S2 http://links.lww.com/ QAD/A854, H77c and H77c-dup for duplicate). Before SVS correction, only 55% of raw E1E2 and NS3 sequences were identical to the H77c sequence. After SVS correction, 99.38% of E1E2 and NS3 consensus sequences were identical to H77c (99.44 and 98.93% for E1E2 and NS3, respectively). The overall error rate prior to SVS correction was 1.53 Â 10 À3 errors per nucleotide, which decreased to 1.41 Â 10 À5 errors per nucleotide (>100-fold reduction) after SVS correction.
Analysis of clinical samples from HIV/HCV coinfected patients showed that prior to SVS correction ( Figure S2 http://links.lww.com/QAD/A854, Raw column), minority variants (defined as <1% of viral population, indicated by color gray) dominated the overall E1E2 and NS3 sequences. Following SVS correction ( Figure S2 http://links.lww.com/QAD/A854, SVS column), the proportion of minority variants (color gray) was significantly reduced. Thus, SVS correction identified the authentic sequences of dominant variants (color red) and unmasked the structure of HCV quasispecies population. Furthermore, in more than half of E1E2 and more than one-third of NS3 amplicons, sequences of dominant variants were different before and after SVS correction, indicating that the SVS procedure not only restored the accurate composition of quasispecies but also corrected the technical artifacts that altered the identity of viral sequences.
Distinct evolutionary patterns of hepatitis C virus quasispecies between structural and nonstructural genes
To investigate long-term evolution of HCV quasispecies, we analyzed the phylogenetic relationship of major sequence variants (defined as !1% of viral population), which together represents $60% of all consensus sequences from patient samples (>40 000 sequences). Phylogenies for the structural gene E1E2 envelope ( Fig. 3 ) and the nonstructural gene NS3 ( Figure S3 http://links.lww.com/QAD/A854) showed different patterns. For E1E2, separate clusters of sequence variants were observed from different time points ( Fig. 3 , patients 2 and 5), showing a predominantly temporal order of evolution, namely shifting to new clades from one visit to the next. In contrast, many sequence overlaps between visits were observed for NS3 ( Figure S3 http:// links.lww.com/QAD/A854), consistent with a transitional order of evolution. These differences in evolutionary patterns were more pronounced in patients 2 and 5, in which more samples were available for analysis. In addition, the envelope sequences showed more diverse major variants (i.e. shorter horizontal bars in E1E2 trees in Fig. 3 and more gray areas in Figure S2 http:// links.lww.com/QAD/A854) compared with NS3. Quasispecies complexity was also significantly higher for E1E2 compared with NS3 (0.44 versus 0.24 for E1E2 and NS3, respectively, P ¼ 4 Â 10 À7 ). Antiretroviral therapy-induced CD4 R T-cell recovery is associated with rapid hepatitis C virus envelope sequence evolution To evaluate the impact of suppressive ART on HCV quasispecies evolution, we compared the rates of nonsynonymous substitutions between the 'early ART' and the 'delayed ART' groups ( Fig. 4) . Overall, envelope sequences showed higher rates of nonsynonymous substitutions than NS3 (average rate of 4.27 Â 10 À3 and 1.80 Â 10 À4 nonsynonymous substitutions per nonsynonymous site per year for E1E2 and NS3 segments, respectively; P < 0.01). The 'early ART' group had a higher rate of nonsynonymous evolution in HCV envelope compared with the 'delayed ART' group (average rate of 6.07 Â 10 À3 and 2.47 Â 10 À3 for early ART and delayed ART, respectively; P ¼ 0.03) (Fig. 4b) , driven primarily by the more rapid sequence turnover in HVR1 in the early ART group (Fig. 4a , sliding window analysis). In contrast, no significant difference in evolutionary rates for NS3 was found between the two groups (average rate of 2 Â 10 À5 and 3.5 Â 10 À4 for the early and the delayed ART groups, respectively; P ¼ 0.16) ( Fig. 4b ).
We next examined temporal changes in HVR1 amino acid sequences using high-resolution sequence logo analysis (Fig. 5 ). In the early ART group, HVR1 sequences were replaced sequentially by new sequences. In contrast, HVR1 sequences remained relatively unchanged in two of three patients in the delayed ART group for over 10 years. Interestingly, for patient 2, several amino acid (AA) changes in HVR1 sequence occurred at year 5.9, which coincided with an increase in CD4 þ T-cell count (from 114 to 553 cells/ml). The AA sequence reverted at year 8 following the decline of CD4 þ T-cell from 553 to 278 cells/ml. Taken together, these data suggest that ART-induced CD4 þ T-cell recovery was associated with rapid amino acid sequence evolution in HCV envelope but not NS3.
Single-variant sequencing identified authentic NS3 resistance-associated variants in HIV/HCV coinfection Naturally occurring NS3 resistance-associated variants (RAVs) have been reported for both HCV monoinfected and HIV/HCV coinfected patients [38, 39] , but their temporal dynamics is unknown. Using SVS, we quantified the temporal evolution of authentic NS3 RAVs. Naturally occurring RAVs were identified in five of the six patients (mean detection limit of 0.1%) ( Figure  S4 http://links.lww.com/QAD/A854 
Discussion
We present an in-depth analysis of HCV quasispecies evolution in HIV/HCV coinfected patients followed up to 11 years. Using SVS, we showed that ART-induced CD4 þ T-cell recovery was associated with rapid nonsynonymous sequence evolution in HCV envelope, and that patients with CD4 þ T-cell depletion and delayed ART had significantly lower rates of HCV envelope evolution. In contrast, the rates of nonsynonymous evolution in NS3 were considerably lower compared with HCV envelope with no significant difference between the two groups. These data are consistent with our hypothesis that ART-induced CD4 þ T-cell recovery enhances anti-HCV envelope antibody response, but not anti-HCV cellular response.
Evolution of envelope sequences (especially HVR1) is driven largely by neutralizing antibodies (nAbs) [7, 20, 28, 40, 41] . During acute HCV infection, an early robust nAbs response is associated with rapid envelope sequence evolution and spontaneous clearance of HCV [6, 7, 40] . In patients who progress to chronic infection, nAb responses are delayed but remain persistent, consistent with increasing rates of evolution in the envelope region [6] [7] [8] [9] [10] . Thus, rapid HCV envelope evolution in the early ART group suggests enhanced nAb response upon CD4 þ T-cell recovery (Figs 4 and 5) . In contrast, lower rates of HCV envelope evolution, 696 AIDS 2016, Vol 30 No 5
Year 0-1 Fig. 3 . Phylogenetic analysis revealed temporal evolution of HCV E1E2 quasispecies over 10 years. A master maximum likelihood (ML) tree (center) was built using dominant sequences from each sample. Sequences from the same patient are shown using the same color in the master tree (center). For each patient, detailed maximum likelihood phylogeny of HCV population is shown using representative E1E2 sequences (!1% in HCV populations). Minority variants (<1% in HCV populations) were excluded for clarity. Longitudinal sequences are indicated by rainbow colors. The length of each horizontal bar indicates the proportion of each variant within the viral population. Highly abundant variants (>80% of the population) are indicated by double bars (e.g. patient 4, blue bar). When two samples from the same year were available, variants from the later samples are marked with an asterisk (e.g. patient 2 and 5). Bootstrap values are shown at major nodes in the master tree (center) and are omitted in the individual trees for clarity. Reference sequences are Bole1a (subtype 1a, solid circle, GenBank accession number: JQ791196.1 [55] ), H77 (subtype 1a, empty circle, GenBank accession number: AF009606) and Con1 (subtype 1b, solid triangle, GenBank accession number: AJ238799). This tree contains sequence information from >16 000 SVS consensus sequences (>50% of all E1E2 consensus sequences) constructed from over 2 million paired-end reads.
particularly with a lack of amino acid changes in the HVR1 for a decade, in the delayed ART group suggest a decline in nAb response from CD4 þ T-cell depletion (Figs 4 and 5 ). Our results are consistent with the recent findings that CD4 þ T-cell depletion by HIV infection results in a global decline in the anti-HCV nAb response, and that increased nAb titers were observed in patients on suppressive ART [24, 25] .
We observed no significant difference in rates of NS3 evolution between the early and the delayed ART groups. Nonsynonymous evolutionary rate in patients with rising CD4 þ T-cell counts approached zero, indicating minimum selective pressure on NS3 over a decade despite CD4 þ T-cell recovery. Nonstructural genes such as NS3 are presumably under selective pressure from HCVspecific cellular immune responses that are likely impaired by HCV-induced mechanisms during chronic infection [8, 28, 29, 42] . Given the largely comparable low evolutionary rates among nonstructural genes (p7, NS2-NS5B) during early chronic HCV infection [28] , our data suggest that HIV infection and ART disproportionally affect HCV-specific humoral responses more than cellular responses, resulting in rapid sequence evolution in the envelope but not NS3. We also note that ART had little effects on HCV RNA levels or viral clearance, consistent with the previous findings that rising nAb response alone is insufficient for HCV clearance, unless accompanied by a reversal of T-cell exhaustion [7, 15, 20, 25, 28, 42] . Nonetheless, because HIV coinfection leads to accelerated progression and ART slows the progression of HCVrelated liver diseases, this disproportional effect on nAb responses and evolution of HCV envelope suggests a potential protective role of nAbs in HCV liver disease progression.
Combined with previous data [24, 25] , our results support the recent finding that coinfected patients who achieved HIV viral suppression with ART had lower rates of hepatic decompensation compared with those who did not maintain HIV suppression [43, 44] . However, despite suppressive ART, coinfected patients continue to have an increased risk of hepatic decompensation compared with HCV-monoinfected individuals [45] , possibly related to ongoing immune dysregulation not reversed by ART. Taken together, these results are consistent with the current DHHS guideline that recommends initiation of ART among HIV/HCV coinfected patients regardless of CD4 þ T-cell count [46] , and support the most recent AASLD/IDSA recommendations that prioritize HIV/ HCV coinfected individuals for consideration of early HCV therapy to reduce the risk of liver disease progression [47] .
SVS represents a substantial technical advance in quantifying accurate proportions of dominant and minority variants compared with conventional PCRbased deep sequencing. First, the number of reads that shared the same random sequence tags varied widely (range: 1-98 124). This suggests that conventional PCR introduces substantial template re-sampling and PCR amplification bias, and therefore can severely skew the proportions of the initial viral populations if uncorrected. SVS correction markedly reduced the effects of PCR bias and template resampling. Second, SVS corrects a large number of nucleotide misincorporation errors, as indicated by the analysis of minority variants ( Figure  S2 http://links.lww.com/QAD/A854) and resistanceassociated variants (Figures S4 and S5 http://links.lww.com/QAD/A854). Strikingly, these artifacts led to incorrect identification of more than half of E1E2 and more than one-third of NS3 dominant variants, highlighting the limitations and the potential risks of conventional clonal or deep sequencing without correction for technical artifacts. Third, the Illumina workflow obviates the need for homopolymer error correction that frequently complicates the analysis of pyrosequencing data [34] [35] [36] . Furthermore, the low error rate for Illumina minimizes base call errors in the primer tags that could lead to the creation of artificial variants and distort quasispecies distributions [33, 48] . Thus, SVS allowed us to determine viral variants and quasispecies population with high accuracy and sensitivity. We note that errors from first-strand DNA synthesis during reverse transcription could not be corrected using SVS. However, these errors are common to all amplification strategies that require first-strand DNA synthesis from viral RNA. Finally, although errors may also be introduced in sequence tags during PCR or nucleotide sequencing, they likely contribute little compared with the effects of template resampling and PCR/sequencing errors. Fig. 5 . Rapid HCV envelope evolution is driven largely by rapid HVR1 amino acid sequence turnover in patients with ARTinduced CD4 R T-cell recovery. Changes in amino acid (AA) sequences in the hypervariable region (HVR)-1 were demonstrated using sequence logos generated by VisSPA (Version 1.6.6, see section Methods). For initial samples, type 1 logos were generated from consensus sequences to demonstrate quasispecies composition. For subsequent visits, type 2 logos were generated, in which only AA changes relative to the initial viral sequences were shown. The height of the type 2 logos indicates relative abundance of amino acid changes [28, 40] . Time intervals (years) from the initial visit to subsequent visits are shown on the left. CD4 þ T-cell count and HCV RNA levels are shown on the right. An average of 986 consensus sequences per sample was used to generate the sequence logos.
Emergence of resistance-associated variants (RAV) is a potential concern for patients receiving direct-acting antiviral (DAA) therapy. Drug resistance develops rapidly with protease inhibitors monotherapy [38, 39] . This is not surprising because polymorphic RAVs (e.g. V55A, Q80K) and minor RAVs preexist in treatment-naive individuals. In four of six patients, HCV populations were dominated by Q80K or V55A over all time points analyzed. In addition, minority RAVs were identified in at least one locus in all but one patient. Among the 10 amino acid sites associated with NS3 resistance [49] [50] [51] , no RAVs were observed in four amino acid sites in any of the samples analyzed ( Figure S4 http://links.lww.com/ QAD/A854), suggesting that substitutions at these sites may incur a high fitness cost in vivo. Each minority RAV was observed in only one patient, except for IV170T, which was found in four of six patients at multiple time points. These results are consistent with the previous data indicating that IV170T has minimal fitness cost compared with wild-type HCV [52] . Although SVR rates are high and are comparable between HCV and HIV/HCV coinfection with new DAAs, treatment failure still occurs in a small number of individuals [53, 54] . Going forward, understanding the significance of preexisting RAVs and their selection during treatment failure would likely require sensitive and accurate methods such as SVS, which can detect authentic RAVs with minimal bioinformatics or statistical manipulations to correct for technical artifacts.
In summary, we report that early ART-induced CD4 þ T-cell recovery is associated with increased rates of HCV evolution in the envelope, but not NS3. Since HCV envelope is the primary target of nAbs, these data suggest HCV-specific nAb response modulated by ART as a potential mechanism for slowing the progression of liver fibrosis in HIV/HCV coinfection. From the technical perspective, the SVS approach should be broadly applicable to evolutionary studies of other hypervariable viruses such as HIV and sensitive detection of drug resistant mutations during antiviral therapy.
